Clinical Trial Update: Study Comparing Bifeprunox to Risperidone in Treatment of Outpatients With Schizophrenia With Weight as Primary Endpoint [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial comparing bifeprunox to risperidone in outpatient schizophrenia, using weight change as the primary endpoint; the study status is termi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Bifeprunox (bifeprunox)
• RISPERIDONE (RISPERIDONE)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Schizophrenia | Phase 3 | Status: TERMINATED